We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA-Antibody Hybrid Molecule Shown to Be Effective Antibacterial Agent

By LabMedica International staff writers
Posted on 18 May 2015
Print article
Image: Alphamers (purple) act as homing beacons, attracting pre-existing anti-alpha-Gal antibodies (green) to the bacterial surface (Photo courtesy of Altermune Technologies).
Image: Alphamers (purple) act as homing beacons, attracting pre-existing anti-alpha-Gal antibodies (green) to the bacterial surface (Photo courtesy of Altermune Technologies).
Image: Dr. Kary Mullis, founder of Altermune Technologies, received the Nobel Prize for chemistry in 1993 for his invention of the polymerase chain reaction (PCR) )Photo courtesy of Altermune Technologies).
Image: Dr. Kary Mullis, founder of Altermune Technologies, received the Nobel Prize for chemistry in 1993 for his invention of the polymerase chain reaction (PCR) )Photo courtesy of Altermune Technologies).
A hybrid molecule comprising an aptamer attached to a trisaccharide terminating with alpha-gal (N-acetyl-glucosamine) was shown in a proof-of-principle study to be an effective antibacterial agent.

Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies, as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. Relative to monoclonal antibodies, aptamers are small, stable, and non-immunogenic.

Humans do not express the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-Gal) epitope. However, as a result of exposure to alpha-Gal in the environment, humans develop a large quantity of circulating antibodies that are specific for this trisaccharide.

Investigators at the University of California, San Diego (USA) developed a DNA aptamer that was able to bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. To the 5′ end of this aptamer they conjugated an alpha-Gal epitope. This hybrid molecule was termed an "alphamer." The intent was that the aptamer segment of the alphamer would attach the molecule to the target bacterium while the alpha-Gal fragment would bind to the body's normally circulating anti-alpha-Gal antibodies.

In a paper published in the May 5, 2015, online edition of the Journal of Molecular Medicine the investigators showed that an anti-GAS alphamer could recruit anti-Gal antibodies to the streptococcal surface in an alpha-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS organisms in human whole blood.

These results constituted the first in vitro proof of concept that alphamers had the potential to redirect preexisting antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response.

"We are picturing a future in which doctors have a case full of pathogen-specific alphamers at their disposal," said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego. "They see an infected patient, identify the causative bacteria, and pull out the appropriate alphamer to instantly enlist the support of the immune system in curing the infection."

The alphamer concept was attributed to contributing author Dr. Kary Mullis, winner of the 1993 Nobel Prize for chemistry for his invention of the polymerase chain reaction (PCR), technique. Dr. Mullis has established a biotech company, Altermune Technologies (Irvine, CA, USA), to develop alphamers into commercially viable therapeutic tools.

Related Links:

University of California, San Diego
Altermune Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.